MCID: PLC011
MIFTS: 52

Pilocytic Astrocytoma malady

Categories: Rare diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Pilocytic Astrocytoma

About this section
Sources:
10Disease Ontology, 45NIH Rare Diseases, 47Novoseek, 12DISEASES, 51Orphanet, 65UMLS, 36MeSH, 42NCIt, 59SNOMED-CT, 66UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Pilocytic Astrocytoma:

Name: Pilocytic Astrocytoma 10 45 47 12 51 65
Juvenile Pilocytic Astrocytoma 45 65
 
Grade I Astrocytic Tumor 10
Piloid Astrocytoma 10

Characteristics:

Orphanet epidemiological data:

51
pilocytic astrocytoma:
Inheritance: Not applicable; Age of onset: All ages

Classifications:



External Ids:

Disease Ontology10 DOID:4851
MeSH36 D001254
NCIt42 C4047
Orphanet51 251612
UMLS via Orphanet66 C0334583
UMLS65 C0334583

Summaries for Pilocytic Astrocytoma

About this section
NIH Rare Diseases:45 Pilocytic astrocytoma is an often benign, slow-growing tumor of the brain or spinal cord. the tumor may be in the form of a cyst and usually does not spread to nearby tissues. symptoms vary depending upon the size and location of the tumor. most symptoms result from increased pressure on the brain and include headaches, nausea, vomiting, balance problems, and vision abnormalities. the underlying cause of a pilocytic astrocytoma is unknown. it most commonly occurs in children and young adults, and in people with neurofibromatosis type 1 (nf1), li-fraumeni syndrome, and tuberous sclerosis. this type of tumor can often be cured with surgery. last updated: 8/9/2013

MalaCards based summary: Pilocytic Astrocytoma, also known as juvenile pilocytic astrocytoma, is related to childhood pilocytic astrocytoma and pilocytic astrocytoma of cerebellum. An important gene associated with Pilocytic Astrocytoma is KIAA1549 (KIAA1549), and among its related pathways are pilocytic astrocytoma and G-protein signaling_K-RAS regulation pathway. Affiliated tissues include the brain, brain and spinal cord, and related mouse phenotypes are adipose tissue and pigmentation.

Disease Ontology:10 An astrocytoma that is characterized by cells that look like fibers when viewed under a microscope and is located in the brain.

Wikipedia:68 Pilocytic astrocytoma or juvenile pilocytic astrocytoma or cystic cerebellar astrocytoma (and its... more...

Related Diseases for Pilocytic Astrocytoma

About this section

Diseases in the Pilocytic Astrocytoma family:

Juvenile Pilocytic Astrocytoma

Diseases related to Pilocytic Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 337)
idRelated DiseaseScoreTop Affiliating Genes
1childhood pilocytic astrocytoma34.6CDKN2A, GFAP, NF1
2pilocytic astrocytoma of cerebellum34.3BRAF, GFAP, SYP
3gliosarcoma29.9CDKN2A, GFAP, IDH1, KDR, KIAA1549, KRAS
4lung cancer29.7BRAF, CDKN2A, ERBB3, FGFR1, HRAS, KDR
5juvenile pilocytic astrocytoma12.6
6pseudoachondroplastic dysplasia 210.6PTPN11, RAF1
7cataract-intellectual disability-hypogonadism syndrome10.6BRAF, KRAS
8nuclear gene-encoded leigh syndrome10.6BRAF, PTPN11, RAF1
9metachondromatosis10.6BRAF, PTPN11, RAF1
10rad21-related cornelia de lange syndrome10.6BRAF, PTPN11, RAF1
11hypogonadotropic hypogonadism-frontoparietal alopecia syndrome10.6IDH1, OLIG2
12tetrasomy 12p10.6HRAS, KRAS
13sigmoid disease10.6HRAS, KRAS
14pilocytic astrocytoma10.5BRAF, IDH1, KIAA1549, NF1
15diencephalic astrocytomas10.5BRAF, IDH1, KIAA1549, NF1
16diabetic encephalopathy10.5HRAS, KRAS
17splenogonadal fusion limb defects micrognatia10.5BRAF, CDKN2A, HRAS
18compartment syndrome10.5NF1, PBX3
19schwannoma of twelfth cranial nerve10.5CDKN2A, NF1, SOX10
20epidermal nevus, somatic10.5HRAS, KRAS
21growth restriction, severe, with distinctive facies10.5HRAS, KRAS, PTPN11
22pyometritis10.5BRAF, CDKN2A, KRAS
23chronic inflammatory demyelinating polyradiculoneuropathy10.5HRAS, KRAS
24angiokeratoma of mibelli10.5CDKN2A, NF1, SOX10
25pineal gland astrocytoma10.5GFAP, NF1
26sweat gland cancer10.5CDKN2A, HRAS, KRAS
27apocrine adenocarcinoma10.5CDKN2A, HRAS, KRAS
28familial abdominal aortic aneurysm10.5BRAF, HRAS, KRAS
29myelofibrosis10.5HRAS, KRAS, NF1, PTPN11
30leukemia, acute myelomonocytic, somatic, somatic10.4HRAS, KRAS, NF1, PTPN11
31connective tissue benign neoplasm10.4CDKN2A, HRAS, KRAS
32pancreatic ductal adenocarcinoma10.4CDKN2A, HRAS, KRAS
33schimmelpenning-feuerstein-mims syndrome, somatic mosaic10.4HRAS, KRAS
34childhood cerebellar neoplasm10.4BRAF, GFAP
35subependymal giant cell astrocytoma10.4GFAP, IDH1, KIAA1549
36tracheal lymphoma10.4CDKN2A, HRAS, KRAS
37bronchitis10.4BRAF, GFAP, IDH1
38breast cancer10.4
39colon small cell carcinoma10.4GFAP, IDH1, KIAA1549
40dubin-johnson syndrome10.4CDKN2A, HRAS, KRAS
41hartnup disorder10.4CDKN2A, HRAS, KRAS
42congenital disorder of glycosylation, type if10.4GFAP, IDH1
43pancreatic somatostatinoma10.4CDKN2A, HRAS, KRAS
44vulvar dystrophy10.4BRAF, HRAS, NF1, PTPN11, RAF1
45anterior spinal artery syndrome10.4GFAP, NF1, SOX10
46tenosynovitis of foot and ankle10.4CDKN2A, HRAS, KRAS
47malignant pineal area germ cell neoplasm10.4BRAF, SYP
48cellular schwannoma10.4GFAP, NF1, SOX10
49liver angiosarcoma10.4IDH1, KIAA1549, SYP
50hypothyroidism due to deficient transcription factors involved in pituitary development or function10.4GFAP, KDR, NF1

Graphical network of the top 20 diseases related to Pilocytic Astrocytoma:



Diseases related to pilocytic astrocytoma

Symptoms for Pilocytic Astrocytoma

About this section

Drugs & Therapeutics for Pilocytic Astrocytoma

About this section

Drugs for Pilocytic Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 152)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
DonepezilapprovedPhase 3, Phase 2271120014-06-43152
Synonyms:
( inverted exclamation markA)-E 2020
1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine
120014-06-4
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-2,3-dihydroinden-1-one
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one
AB1004836
AC-6969
AC1L1FAE
AKOS000277311
Aricept
Aricept ODT
C24H29NO3
CHEBI:53289
CHEMBL502
CID3152
D07869
DB00843
Domepezil
Donaz
Donaz (TN)
 
Donepezil
Donepezil (INN)
Donepezil Hydrochloride
Donepezil [INN:BAN]
Donepezil hydrochloride
Donepezilo
Donepezilum
Eranz
I06-0343
KBio2_002144
KBio2_004712
KBio2_007280
KBioSS_002144
LS-81819
MolPort-000-881-588
MolPort-003-847-014
NCGC00167537-01
Oprea1_188452
Spectrum5_001662
Spectrum_001664
TL8000531
UNII-8SSC91326P
2
Fentanylapproved, illicit, investigationalPhase 3705437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Abstral
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl - Novaplus
Fentanyl Citrate
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
 
Fentanyl-12
Fentanyl-25
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Lazanda
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
Subsys
UNII-UF599785JZ
fentanyl
3
Vincristineapproved, investigationalPhase 2, Phase 3, Phase 18632068-78-2, 57-22-75978
Synonyms:
22-Oxovincaleukoblastin
22-Oxovincaleukoblastine
28379-27-3
57-22-7
AC1L1LJC
C07204
C46H56N4O10
CCRIS 5763
CHEBI:28445
CID5978
D08679
DB00541
EINECS 200-318-1
HMS2090E19
HSDB 3199
Indole alkaloid
LCR
LS-228
Leurocristine
Lilly 37231 (1:1 sulfate salt)
Liposomal Vincristine
Marqibo
NCGC00163700-01
NCI-C04864
NCI60_026703
NSC-67574
Onco TCS
 
Oncovin
Oncovin (1:1 sulfate salt)
Oncovine
Tecnocris
Tecnocris (TN)
UNII-5J49Q6B70F
VCR
VIN
Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine
Vincasar
Vincasar (1:1 sulfate salt)
Vincasar PFS
Vincrex
Vincrex (1:1 sulfate salt)
Vincristin
Vincristina
Vincristina [DCIT]
Vincristine (INN)
Vincristine Sulfate
Vincristine Sulfate PFS
Vincristine [INN:BAN]
Vincristinum
Vincristinum [INN-Latin]
Vincrstine
Vincrystine
Vinkristin
Z-D-Val-Lys(Z)-OH
vincristine
4
ProcarbazineapprovedPhase 2, Phase 368671-16-94915
Synonyms:
1-Methyl-2-(P-(isopropylcarbamoyl)benzyl)hydrazine
1-Methyl-2-(p-(isopropylcarbamoyl)benzyl)hydrazine
2-(P-Isopropylcarbamoylbenzyl)-1-methylhydrazine
2-(p-Isopropylcarbamoylbenzyl)-1-methylhydrazine
366-70-1 (mono-hydrochloride)
4-((2-Methylhydrazino)methyl)-N-isopropylbenzamide
4-[(2-methylhydrazinyl)methyl]-N-propan-2-ylbenzamide
671-16-9
AC-4547
AC1L1J8E
Ambap671-16-9
BIDD:GT0183
BPBio1_001369
BRN 0958270
BSPBio_001244
Benzamide, N-(1-methylethyl)-4-((2-methylhydrazino)methyl)- (9CI)
C07402
C12H19N3O
CAS-366-70-1
CB 400-497
CCRIS 2389
CHEMBL1321
CID4915
D08423
DB01168
EINECS 211-582-2
HMS2090J09
HSDB 3250
I01-8931
IBZ
Ibenzmethyzin
Ibenzmethyzine
LS-7671
MBH
MIH
Matulane
MolPort-005-940-370
N-(1-Methylethyl)-4-((2-methylhydrazino)methyl)benzamide
 
N-(1-Methylethyl)-4-[(2-methylhydrazino)methyl]benzamide
N-4-Isopropylcarbamoylbenzyl-N'-methylhydrazine
N-4-Isopropylcarbamoylbenzyl-n'-methylhydrazine
N-Isopropyl-4-[(2-methylhydrazino)methyl]benzamide
N-Isopropyl-P-(2-methylhydrazinomethyl)-benzamide
N-Isopropyl-alpha-(2-methylhydrazino)-P-toluamide
N-Isopropyl-alpha-(2-methylhydrazino)-p-toluamide
N-Isopropyl-p-(2-methylhydrazinomethyl)-benzamide
NCGC00016438-01
NCGC00016438-02
NCI60_041703
NCIOpen2_004074
NSC-77213
Natulan
Natulanar
P-(2-Methylhydrazinomethyl)-N-isopropylbenzamide
PCX
Prestwick0_001112
Prestwick1_001112
Prestwick2_001112
Prestwick3_001112
Procarbazin
Procarbazin [German]
Procarbazina
Procarbazina [INN-Spanish]
Procarbazine (INN)
Procarbazine Monohydrochloride
Procarbazine [INN:BAN]
Procarbazine hydrochloride
Procarbazinum
Procarbazinum [INN-Latin]
Ro 4-6467
Ro 4-6467/1
SPBio_003112
SRI-10847
UNII-35S93Y190K
p-(2-Methylhydrazinomethyl)-N-isopropylbenzamide
p-(N'-Methylhydrazinomethyl)-N-isopropylbenzamide
procarbazine
5
DopamineapprovedPhase 3308462-31-7, 51-61-6681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine Hcl
Dopamine Hydrochloride
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
 
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
6
LomustineapprovedPhase 2, Phase 37613010-47-43950
Synonyms:
(Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea
(Cloro-2-etil)-1-cicloesil-3-nitrosourea
(Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian]
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]
1-(2-Chloroethyl)-3-cyclohexylnitrosourea
13010-47-4
AC-10564
AC1L1H2T
AI3-52779
BRN 2125058
Belustine
Bristol Myers Squibb Brand of Lomustine
Bristol-Myers Squibb Brand of Lomustine
C9H16ClN3O2
CCNU
CCNU [Chloroethyl nitrosoureas]
CCRIS 860
CHEMBL514
CID3950
CINU
Cecenu
CeeNU
CeeNU (TN)
CeeNU, CCNU, Lomustine
Ceenu
Chloroethylcyclohexylnitrosourea
Cyclohexyl chloroethyl nitrosourea
D00363
D008130
DB01206
EINECS 235-859-2
FT-0083566
Gleostine
 
HMS2090A17
HSDB 6519
I06-0087
ICIG 1109
LS-728
Lomustina
Lomustina [INN-Spanish]
Lomustine
Lomustine (USAN/INN)
Lomustine [USAN:BAN:INN]
Lomustine medac Brand
Lomustinum
Lomustinum [INN-Latin]
MolPort-001-768-818
N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea
N-(2-Chloroethyl)-n'-cyclohexyl-N-nitrosourea
NCGC00167466-01
NCI-C04740
NCI60_041743
NCIMech_000220
NPFAPI-06
NSC 79037
NSC-79037
NSC79037
OR5087
RB 1509
Rhone Poulenc Rorer Brand of Lomustine
Rhone-Poulenc Rorer Brand of Lomustine
S1840_Selleck
SRI 2200
UNII-7BRF0Z81KG
WLN: L6TJ AMVNNO&2G
ZINC03831006
lomustine
medac Brand of Lomustine
7
Histamine PhosphateapprovedPhase 390651-74-165513
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
EINECS 200-118-4
 
H0147
Histamine Positive Skin Test Control
Histamine Positive skin test control
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
Histaminum
LS-78569
UNII-QWB37T4WZZ
8
Methylphenidateapproved, investigationalPhase 3364113-45-14158
Synonyms:
.alpha.-Phenyl-2-piperidineacetic acid methyl ester
113-45-1
2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester
2-Piperidineacetic acid, alpha-phenyl-, methyl ester
298-59-9 (hydrochloride)
4311/B Ciba
AC1L1HJM
C 4311
C07196
CHEBI:6887
CHEMBL796
CID4158
Calocain
Centedein
Centedrin
Centedrine
Centredin
Concerta
D-Methylphenidate HCl
D04999
DB00422
DB06701
DEA No. 1724
Daytrana
Daytrana (TN)
EINECS 204-028-6
Focalin
Focalin XR
HSDB 3126
L001307
LS-565
METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R)
MPH
Meridil
Metadate
Metadate CD
Metadate ER
MethyPatch
Methyl (2-phenyl-2-(2-piperidyl)acetate)
Methyl alpha-phenyl-alpha-(2-piperidyl)acetate
Methyl alpha-phenyl-alpha-2-piperidinylacetate
Methyl phenidate
Methyl phenidyl acetate
 
Methyl phenidylacetate
Methylfenidan
Methylin
Methylin ER
Methylofenidan
Methylphen
Methylphenidan
Methylphenidate
Methylphenidate (USAN/INN)
Methylphenidate HCl
Methylphenidate Hydrochloride
Methylphenidate [INN:BAN]
Methylphenidate hydrochloride
Methylphenidatum
Methylphenidatum [INN-Latin]
Methylphenidylacetate hydrochloride
Methypatch
Metilfenidat hydrochloride
Metilfenidato
Metilfenidato [INN-Spanish]
Metilfenidato [Italian]
MolPort-001-779-620
NCI-C56280
PMS-Methylphenidate
Phenidylate
Plimasine
Quillivant XR
Riphenidate
Ritalin
Ritalin LA
Ritalin SR
Ritalin hydrochloride
Ritalin-SR
Ritaline
Ritcher Works
Ritcher works
Tsentedrin
UNII-207ZZ9QZ49
alpha-Phenyl-2-piperidineacetic acid methyl ester
alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester
d-methylphenidate HCl
methyl 2-phenyl-2-piperidin-2-ylacetate
methyl phenyl(piperidin-2-yl)acetate
methylphenidate
nchembio.2007.55-comp28
9
CyproheptadineapprovedPhase 315129-03-32913
Synonyms:
1-Methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine
1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine
1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine
129-03-3
4-(5-Dibenzo(a,D)cyclohepten-5-ylidine)-1-methylpiperidine
4-(5-Dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine
4-(5H-Dibenzo(a,D)cyclohepten-5-ylidene)-1-methylpiperidine
4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidene
4-(5H-Dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine
4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-methylpiperidine
4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine
4-Dibenzo[a,D]cyclohepten-5-ylidene-1-methyl-piperidine
41354-29-4
5-(1-Methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene
5-(1-methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene
5-20-08-00500 (Beilstein Handbook Reference)
AC1L1ER8
AKOS004119847
Axoprol
BIDD:GT0324
BPBio1_000096
BPBio1_000155
BRD-K28143534-001-01-4
BRD-K28143534-003-03-6
BRN 1685976
BSPBio_000086
Biomol-NT_000131
C06935
CAS-969-33-5
CCRIS 5232
CHEBI:4046
CHEMBL516
CID2913
CYPROHEPTADINE
Ciproheptadina
Ciproheptadina [INN-Spanish]
Ciprovit
Ciprovit (TN)
Cypoheptadine
Cyproheptadiene
Cyproheptadin
Cyproheptadine
Cyproheptadine (INN)
 
Cyproheptadine Hcl
Cyproheptadine Hydrochloride
Cyproheptadine [INN:BAN]
Cyproheptadinum
Cyproheptadinum [INN-Latin]
D07765
DB00434
Dibenzosuberonone/Cyproheptadine
Dihexazin
Dronactin
EINECS 204-928-9
Eiproheptadine
Glutodina
HMS2090P20
HSDB 3048
L001016
LS-114933
Lopac-C-6022
Lopac0_000246
MK 141
MolPort-002-507-777
NCGC00015252-01
NCGC00015252-02
NCGC00015252-03
NCGC00015252-09
NCGC00024293-02
NCGC00024293-04
NCGC00024293-05
Oprea1_498140
PDSP1_001229
PDSP2_001213
Periactin
Periactine
Periactinol
Prestwick0_000103
Prestwick1_000103
Prestwick2_000103
Prestwick3_000103
SPBio_002025
STK802098
Tocris-0996
UNII-2YHB6175DO
Viternum
nchembio.559-comp10
10Anesthetics, IntravenousPhase 31943
11Tubulin ModulatorsPhase 2, Phase 3, Phase 14279
12AnalgesicsPhase 39358
13Analgesics, OpioidPhase 32304
14AnestheticsPhase 37385
15Central Nervous System StimulantsPhase 3, Phase 21721
16Anesthetics, GeneralPhase 32274
17NarcoticsPhase 32709
18Antineoplastic Agents, PhytogenicPhase 2, Phase 3, Phase 1, Phase 04294
19Central Nervous System DepressantsPhase 310016
20Liver ExtractsPhase 3, Phase 2, Phase 13572
21Antimitotic AgentsPhase 2, Phase 3, Phase 14296
22Cholinesterase InhibitorsPhase 3, Phase 2498
23Cholinergic AgentsPhase 3, Phase 23243
24Peripheral Nervous System AgentsPhase 318510
25Neurotransmitter AgentsPhase 3, Phase 214795
26Nootropic AgentsPhase 3, Phase 2604
27pancreatic polypeptidePhase 3, Phase 120
28Dermatologic AgentsPhase 3, Phase 2, Phase 14555
29Dopamine AgentsPhase 33084
30Dopamine Uptake InhibitorsPhase 3925
31Serotonin AntagonistsPhase 31175
32Neurotransmitter Uptake InhibitorsPhase 32857
33Dexmethylphenidate HydrochloridePhase 316
34Histamine H1 AntagonistsPhase 3688
35Anti-Allergic AgentsPhase 31312
36Serotonin AgentsPhase 32668
37Gastrointestinal AgentsPhase 36401
38AntipruriticsPhase 3619
39
histaminePhase 390675614-87-8, 51-45-6774
Synonyms:
.beta.-Imidazolyl-4-ethylamine
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1avn
1qft
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-imidazol-5-yl)ethanamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-yl-Ethylamine
2-Imidazol-4-ylethylamine
2-[4-Imidazolyl]ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
5-Imidazoleethylamine
51-45-6
53290_FLUKA
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
BSPBio_001117
BSPBio_002124
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
Histamine
Histamine (DCF)
Histamine Base
Histamine [USAN]
Histamine, Free Base
Histaminum
 
Histaminum (TN)
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L-Histamin base
L-Histamine
L-histamine
L000292
LS-75835
Lopac-H-7250
Lopac0_000595
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
ST073926
STK346752
STOCK5S-55669
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
Spectrum_000845
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
[3H]histamine
b-Imidazolyl-4-ethylamine
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
beta-aminothethylglyoxaline
bmse000744
histamine
nchembio.87-comp54
nchembio714-comp1
40Histamine AntagonistsPhase 3826
41
SerotoninPhase 3314750-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
42ColaNutraceuticalPhase 3, Phase 11768
43
Modafinilapproved, investigationalPhase 219268693-11-84236
Synonyms:
Dea No. 1680
Modafinil
Modafinil [USAN:INN]
Modafinil [Usan:Inn]
Modafinilo
Modafinilo [Spanish]
 
Modafinilum
Modafinilum [Latin]
Moderateafinil
Modiodal
Provigil
Sparlon
modafinil
44
TamoxifenapprovedPhase 235010540-29-12733526
Synonyms:
(Z)-1-(p-Dimethylaminoethoxyphenyl)-1,2-diphenyl-1-butene
(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(4-(1,2-diphenylbut-1-enyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(Para-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine
(Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine (IUPAC)
(Z)-2-[4-(1,2)-DIPHENYL-1-BUTENYL)-PHENOXY]-N,N-DIMETHYLETHANAMINE
(Z)-2-[p-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
,citrate
1-P-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-.beta.-Dimethylamino-ethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
10540-29-1
1ya4
2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine
54965-24-1 (citrate)
AC1MBZ3R
Apo-Tamox
Apo-tamox
BIDD:ER0008
BIDD:GT0009
BIDD:PXR0003
BPBio1_000278
BRD-K93754473-001-02-9
BRD-K93754473-048-05-3
BSPBio_000252
BSPBio_001150
BSPBio_001982
C07108
C26H29NO
CCRIS 3275
CHEBI:41774
CHEMBL83
CID2733526
Citofen
Crisafeno
D08559
DB00675
Diemon
EINECS 234-118-0
Gen-Tamoxifen
Gen-tamoxifen
HMS1362J11
HMS1792J11
HMS1990J11
HMS2090N08
HSDB 6782
ICI 47699
ICI-46,474
ICI-47699
IDI1_000258
IDI1_002170
Istubol
Kessar
L024126
LS-393
Lopac0_001203
MLS001332535
MLS001332536
MolPort-003-850-384
 
NCGC00024928-01
NCGC00024928-03
NCGC00024928-04
NCGC00024928-05
NCGC00024928-07
NCGC00024928-08
NCGC00024928-09
NCGC00024928-12
NSC727681
Noltam
Nolvadex
Nolvadex-D
Nourytam
Novaldex
Novo-Tamoxifen
Oncomox
PMS-Tamoxifen
Pms-Tamoxifen
Prestwick2_000146
Prestwick3_000146
QTL1_000079
Retaxim
SMR000059172
ST50511785
Soltamox
Spectrum5_001417
Spectrum5_002043
T5648_SIGMA
TAMOXIFEN (TAMOXIFEN CITRATE (54965-24-1))
TRANS FORM OF TAMOXIFEN
Tamizam
Tamofen
Tamone
Tamoplex (TN)
Tamoxasta
Tamoxen
Tamoxifen
Tamoxifen (INN)
Tamoxifen (TN)
Tamoxifen (Z)
Tamoxifen Citrate
Tamoxifen [INN:BAN]
Tamoxifen and its salts
Tamoxifene
Tamoxifene [INN-French]
Tamoxifeno
Tamoxifeno [INN-Spanish]
Tamoxifenum
Tamoxifenum [INN-Latin]
Tamoxifène
Tocris-0999
Tomaxithen
Trans-Tamoxifen
UNII-094ZI81Y45
UPCMLD-DP027
Valodex
Zemide
cMAP_000044
nchembio.140-comp7
nchembio.76-comp1
nchembio732-comp3
tamoxifen
trans-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethylamine
trans-Tamoxifen
45
Doxorubicinapproved, investigationalPhase 2, Phase 0158223214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
46
CisplatinapprovedPhase 2, Phase 1254015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatin
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinol-aq
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
47
CarboplatinapprovedPhase 2, Phase 1188541575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
48
Irinotecanapproved, investigationalPhase 1, Phase 2104497682-44-5, 100286-90-660838
Synonyms:
(+)-Irinotecan
(4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE
(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate
1u65
97682-44-5
AC-7469
AC1L1U0Z
AC1Q6PGI
BRD-K08547377-003-02-4
BSPBio_002346
Bio-0054
Biotecan
Biotecan (TN)
C16641
C33H38N4O6
CHEBI:105985
CHEMBL481
CID60838
CP0
Campothecin-11
Campto
Camptosar
 
Camptosar, Campto, CPT-11, Irinotecan
Camptothecin-11
D08086
DB00762
FT-0083650
HSDB 7607
IRINOTECAN HYDROCHLORIDE Trihydrate
IRINOTECAN, CPT-11
Irinotecan
Irinotecan (INN)
Irinotecan Hcl
Irinotecan Hydrochloride
Irinotecan Hydrochloride Trihydrate
Irinotecan [INN:BAN]
Irinotecan hydrochloride
Irinotecanum
Irinotecanum [INN-Latin]
LS-44589
NCI60_005051
NSC728073
S1198_Selleck
TL8006026
UNII-7673326042
irinotecan
49
Gefitinibapproved, investigationalPhase 2330184475-35-2123631
Synonyms:
184475-35-2
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
4-(3'-chloro-4'-Fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine
AC-1556
AC1L3X0A
AKOS000280752
BCB03_000781
Bio-0046
C419708
CCRIS 9011
CHEBI:49668
CHEMBL939
CID123631
CU-00000000396-1
D01977
DB00317
DB07998
EC-000.2409
EN002708
FT-0081035
Gefitini
Gefitinib
Gefitinib (JAN/USAN/INN)
Gefitinib [USAN]
Gefitinib, Iressa, ZD1839
HMS2089B19
I01-1227
IRE
 
Iressa
Iressa (TN)
Iressa(TM)
Irressat
K00240
KBioSS_002241
Kinome_3321
Kinome_3322
LS-139916
MolPort-000-883-335
N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
N-(3-chloro-4-Fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine
NCGC00159455-02
NCGC00159455-03
NSC715055
S1025_Selleck
STK621310
UNII-S65743JHBS
ZD 1839
ZD-1839
ZD-1839, Iressa, Gefitinib
ZD1839
ZINC19632614
gefitinib
nchembio.117-comp18
nchembio866-comp14
50
CarmustineapprovedPhase 2, Phase 1207154-93-82578
Synonyms:
1,3-BIS(CHLOROETHYL)-1-NITROSOUREA
1,3-Bis(.beta.-chloroethyl)-1-nitrosourea
1,3-Bis(2-chloroethyl)-1-nitrosourea
1,3-Bis(2-chloroethyl)nitrosourea
1,3-Bis(beta-chloroethyl)-1-nitrosourea
154-93-8
AC-10563
AC1L1DZQ
AI3-52216
BCNU
BCNU [Chloroethyl nitrosoureas]
BRN 2049744
Becenum
Becenun
Bi CNU
BiCNU
BiCNU (TN)
Bicnu
Bicnu (tn)
Bio-0118
Bis(2-chloroethyl)1-nitrosourea
Bis(2-chloroethyl)nitrosourea
Bis(chloroethyl)nitrosourea
Bis-N,N'-(chloroethyl)nitrosourea
Bischlorethylnitrosourea
Bischlorethylnitrosurea
Bischloroethyl nitrosourea
Bischloroethyl nitrosourea [Chloroethyl nitrosoureas]
Bischloroethylnitrosourea
C 0400
C0400_SIGMA
C5H11Cl2N3O2
CCRIS 810
CHEBI:3423
CHEMBL513
CID2578
Carmubris
Carmustin
Carmustina
Carmustina [INN-Spanish]
Carmustine
Carmustine (USAN/INN)
Carmustine [USAN:INN:BAN]
Carmustinum
Carmustinum [INN-Latin]
D002330
D00254
DB00262
DTI 015
DivK1c_000835
EINECS 205-838-2
 
EU-0100188
FDA 0345
FIVB
FT-0083563
Gliadel
Gliadel Wafer
Gliadel, BCNU, NSC-409962, Becenun, Carmustine
HMS2092J22
HMS502J17
I14-11976
IDI1_000835
KBio1_000835
KBio2_000745
KBio2_003313
KBio2_005881
KBioGR_001296
KBioSS_000745
LS-890
Lopac-C-0400
Lopac0_000188
MLS001333962
MolPort-003-665-505
N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA
N,N'-Bis(2-chloroethyl)-N-nitrosourea
NCGC00015204-01
NCGC00015204-02
NCGC00015204-06
NCGC00093665-01
NCGC00093665-02
NCGC00093665-03
NCGC00093665-04
NCI-C04773
NCI60_003931
NINDS_000835
NSC 409962
NSC-409962
NSC409962
Nitrumon
Prestwick_997
S1521_Selleck
SK 27702
SMR000058426
SRI 1720
STK624770
Spectrum4_000888
Spectrum5_000920
Spectrum_000265
UNII-U68WG3173Y
WLN: ONN2GVM2G
ZINC03830387
bis-chloroethylnitrosourea
carmustine
carmustine in ethanol

Interventional clinical trials:

(show top 50)    (show all 66)
idNameStatusNCT IDPhase
1Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
2Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain TumorsCompletedNCT00369785Phase 3
3Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade GliomaActive, not recruitingNCT00003375Phase 2, Phase 3
4Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for CancerTerminatedNCT01132547Phase 3
5Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain TumorsTerminatedNCT00031798Phase 3
6Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant GliomaCompletedNCT00112736Phase 1, Phase 2
7Gefitinib in Treating Patients With Recurrent or Progressive CNS TumorsCompletedNCT00025675Phase 2
8Combination Chemotherapy and Tamoxifen in Treating Patients With Solid TumorsCompletedNCT00002608Phase 2
9Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain TumorsCompletedNCT01032200Phase 2
10Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord TumorsCompletedNCT00541138Phase 2
11Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant GliomaCompletedNCT00498927Phase 2
12Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain CancersCompletedNCT00002752Phase 1, Phase 2
13Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for GliomasCompletedNCT00274755Phase 2
14Imatinib Mesylate in Treating Patients With GliomasCompletedNCT00039364Phase 2
15Temozolomide in Treating Patients With Low-Grade GliomaCompletedNCT00313729Phase 2
16Temozolomide in Treating Patients With Progressive Low-Grade GliomaCompletedNCT00003466Phase 2
17Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain TumorsCompletedNCT00003461Phase 1, Phase 2
18Donepezil or EGb761 in Improving Neurocognitive Function in Patients Who Have Previously Undergone Radiation Therapy for Primary Brain Tumor or Brain MetastasesCompletedNCT00070161Phase 2
19Imatinib Mesylate in Treating Patients With Recurrent Malignant Glioma or MeningiomaCompletedNCT00010049Phase 1, Phase 2
20Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade GliomaCompletedNCT00003467Phase 2
21Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway GliomaRecruitingNCT01553149Phase 2
22Phase II Pegylated InterferonRecruitingNCT02343224Phase 2
23A Phase I Study of Mebendazole for the Treatment of Pediatric GliomasRecruitingNCT01837862Phase 1, Phase 2
24Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal CancerRecruitingNCT00445965Phase 2
25Antineoplaston Therapy in Treating Patients With Brain TumorsRecruitingNCT00003457Phase 2
26Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade GliomaActive, not recruitingNCT01089101Phase 1, Phase 2
27Antineoplaston Therapy in Treating Patients With Low-Grade AstrocytomaActive, not recruitingNCT00003471Phase 2
28Photodynamic Therapy (PDT) For Recurrent High Grade GliomasActive, not recruitingNCT01966809Phase 2
29Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed GlioblastomaActive, not recruitingNCT00553150Phase 1, Phase 2
30Bevacizumab in Recurrent Grade II and III GliomaActive, not recruitingNCT01164189Phase 2
31Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell LymphomaActive, not recruitingNCT00939770Phase 1, Phase 2
32Functional Magnetic Resonance Imaging and 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Treating Patients With Newly Diagnosed Brain TumorsWithdrawnNCT00005083Phase 2
33RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant GliomaCompletedNCT01119599Phase 1
34Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
35Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other CancersCompletedNCT00498979Phase 1
36Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to TreatmentCompletedNCT00544284Phase 1
37Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant GliomaCompletedNCT00509431Phase 1
38MS-275 in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00020579Phase 1
39BCX-1777 in Treating Patients With Refractory CancerCompletedNCT00073944Phase 1
40Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal CancerCompletedNCT00003022Phase 1
41Thalidomide and Docetaxel in Treating Patients With Advanced CancerCompletedNCT00049296Phase 1
42Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory LymphomasCompletedNCT00019019Phase 1
43Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid TumorsCompletedNCT00008086Phase 1
44Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent CancerCompletedNCT00006368Phase 1
45Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain TumorsCompletedNCT00003484Phase 1
46Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or LymphomaCompletedNCT01273090Phase 1
47Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade GliomasRecruitingNCT02186509Phase 1
48Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain TumorsRecruitingNCT00002647Phase 1
49Photodynamic Therapy (PDT) for Brain TumorsActive, not recruitingNCT01682746Phase 1
50Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial GliomasActive, not recruitingNCT00083096Phase 1

Search NIH Clinical Center for Pilocytic Astrocytoma

Genetic Tests for Pilocytic Astrocytoma

About this section

Anatomical Context for Pilocytic Astrocytoma

About this section

MalaCards organs/tissues related to Pilocytic Astrocytoma:

33
Brain, Spinal cord, Cerebellum, Liver, Bone, T cells, Lung

FMA organs/tissues related to Pilocytic Astrocytoma:

16
The brain

Animal Models for Pilocytic Astrocytoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Pilocytic Astrocytoma:

38 (show all 31)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000537510.0BRAF, KIAA1549, NTRK2, OLIG2, PBX3, PTPN11
2MP:00011869.9BRAF, CDKN2A, ERBB3, KRAS, NF1, PTPN11
3MP:00053709.8BRAF, CDKN2A, KDR, KRAS, NF1, NTRK2
4MP:00053779.6APOD, BRAF, FGFR1, KRAS, NF1, NTRK2
5MP:00053829.6BRAF, FGFR1, HRAS, KRAS, NF1, PBX3
6MP:00030129.6CDKN2A, FGFR1, HRAS, KDR, KRAS, OLIG2
7MP:00053809.5BRAF, CDKN2A, ERBB3, FGFR1, KDR, KRAS
8MP:00020069.4BRAF, CDKN2A, ERBB3, HRAS, KRAS, NF1
9MP:00053819.4BRAF, CDKN2A, ERBB3, FGFR1, GFAP, KRAS
10MP:00053799.3BRAF, CDKN2A, ERBB3, FGFR1, HRAS, KRAS
11MP:00053919.3BRAF, CDKN2A, FGFR1, GFAP, KDR, KRAS
12MP:00053699.1BRAF, CDKN2A, ERBB3, FGFR1, GFAP, KDR
13MP:00107719.0BRAF, CDKN2A, ERBB3, FGFR1, HRAS, KDR
14MP:00053879.0BRAF, CDKN2A, ERBB3, FGFR1, GFAP, IDH1
15MP:00028738.9BRAF, ERBB3, FGFR1, GFAP, HRAS, KDR
16MP:00053888.7BRAF, CDKN2A, ERBB3, HRAS, IDH1, KDR
17MP:00053858.7APOD, BRAF, CDKN2A, ERBB3, FGFR1, GFAP
18MP:00053848.6BRAF, CDKN2A, ERBB3, FGFR1, GFAP, KDR
19MP:00053908.5BRAF, CDKN2A, FGFR1, HRAS, IDH1, KDR
20MP:00053788.2BRAF, CDKN2A, ERBB3, FGFR1, GFAP, HRAS
21MP:00053768.1APOD, BRAF, CDKN2A, ERBB3, FGFR1, GFAP
22MP:00053868.0APOD, BRAF, CDKN2A, ERBB3, FGFR1, GFAP
23MP:00036317.9APOD, BRAF, CDKN2A, ERBB3, FGFR1, GFAP
24MP:00107687.9APOD, BRAF, CDKN2A, ERBB3, FGFR1, GFAP

Publications for Pilocytic Astrocytoma

About this section

Articles related to Pilocytic Astrocytoma:

(show top 50)    (show all 342)
idTitleAuthorsYear
1
Giant cystic lymphangioma originating from the cardia of the stomach: A case report. (27168832)
2016
2
Hepatitis D Virus: Introduction and Epidemiology. (26134842)
2015
3
Vernal Keratoconjunctivitis and immune-mediated diseases: One unique way to symptom control? (25692810)
2015
4
Baseline predictors of visual acuity and retinal thickness in patients with retinal vein occlusion. (25829817)
2015
5
Pulmonary Tumor Embolism Derived From Stomach Cancer Observation With Serial 18F-FDG PET/CT. (25247270)
2014
6
Does self-construal predict activity in the social brain network? A genetic moderation effect. (24009354)
2014
7
Telomerase and hTERT: can they serve as markers for gastric cancer diagnosis? (24914385)
2014
8
Promoter-bound trinucleotide repeat mRNA drives epigenetic silencing in fragile X syndrome. (24578575)
2014
9
Work-Related Treatment for Major Depressive Disorder and Incapacity to Work: Preliminary Findings of a Controlled, Matched Study. (25402222)
2014
10
An autopsy case of Hermansky-Pudlak syndrome: a case report and review of the literature on treatment. (25447654)
2014
11
Bullous hemorrhagic retinal detachment because of massive subretinal hemorrhage in patients with age-related macular degeneration. (23518899)
2013
12
Physical therapy for airway clearance improves cardiac autonomic modulation in children with acute bronchiolitis. (24271093)
2013
13
Perceptions and acceptability of mHealth interventions for improving patient care at a community-based HIV/AIDS clinic in Uganda: a mixed methods study. (23452084)
2013
14
inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations. (23160462)
2013
15
Tobacco smoking produces greater striatal dopamine release in G-allele carriers with mu opioid receptor A118G polymorphism. (22516252)
2012
16
The METEOR study of diabetes and other metabolic disorders in patients with schizophrenia treated with antipsychotic drugs. I. Methodology. (20683849)
2010
17
An adenosine derivative compound, IFC305, reverses fibrosis and alters gene expression in a pre-established CCl(4)-induced rat cirrhosis. (19914391)
2010
18
Molecular basis of severe myoclonic epilepsy in infancy. (19203854)
2009
19
Community-acquired Methicillin-resistant Staphylococcus aureus Periorbital Cellulitis: A Problem Here to Stay. (19273945)
2009
20
Genome-wide linkage and association analyses to identify genes influencing adiponectin levels: the GEMS Study. (19165155)
2009
21
Involvement of a Stat3 binding site in inflammation-induced enteric apelin expression. (18818315)
2008
22
Analysis of molecular background of hereditary haemorrhagic telangiectasia--Rendu-Osler-Weber disease--preliminary results]. (19205515)
2008
23
Epigenetic silencing of the interferon regulatory factor ICSBP/IRF8 in human multiple myeloma. (18922617)
2008
24
Von Willebrand disease and angiodysplasia responding to atorvastatin. (18510690)
2008
25
Altered venous capacitance as a cause of postprandial hypotension in multiple system atrophy. (17139443)
2007
26
Functional characterization of both MAP kinases of the human malaria parasite Plasmodium falciparum by reverse genetics. (17651389)
2007
27
Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. (15746193)
2005
28
Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis. (15855637)
2005
29
Serum iron, copper and zinc concentrations and risk of cancer mortality in US adults. (15036223)
2004
30
Influenza viruses and atherosclerosis: the role of atherosclerotic plaques in prolonging the persistent form of influenza infection]. (12741353)
2003
31
Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease. (14560148)
2003
32
Prognostic value of initial surgical procedure for patients with uterine sarcoma: analysis of 123 patients. (12807231)
2003
33
PNRC2 is a 16 kDa coactivator that interacts with nuclear receptors through an SH3-binding motif. (11574675)
2001
34
Connexins: a connection with the skin. (10772382)
2000
35
Morphological and functional changes of the arterial wall in subjects at risk of atherosclerosis and in patients with peripheral arterial occlusive disease. (9409176)
1997
36
An outbreak of acute conjunctivitis due to coxsackie A24 virus in Delhi. (9282517)
1997
37
Midline interhemispheric fusion associated with atypical callosal dysgenesis: a mild type of holoprosencephaly. (8826753)
1996
38
Normal and expanded Huntington's disease gene alleles produce distinguishable proteins due to translation across the CAG repeat. (8521295)
1995
39
The effects of naloxone on retinal ischemia in rats. (8083567)
1994
40
Interaction of thyroid hormones with immunoglobulins isolated from human blood serum. II. Structural elements and localization of thyroxine-binding segment in the immunoglobulin M molecule]. (8117839)
1994
41
Regulation of CCK mRNA in the human neuroepithelioma cell line SK-N-MCIXC in response to second messenger activators. (7694875)
1993
42
Autoantibodies and circulating immune complexes in sera from patients with hepatitis B virus-related chronic liver disease. (1730154)
1992
43
Cogan's syndrome: auditory and medical management. (1581598)
1992
44
Response to autoimmune enteropathy to cyclosporin A therapy. (1752480)
1991
45
Renal physiology of renal artery stenosis. Implications for captopril-stimulated renography. (1777181)
1991
46
Synthesis of N-[N-(4-deoxy-4-amino-10-methylpteroyl)-4-fluoroglutamyl]- gamma-glutamate, an unusual substrate for folylpoly-gamma-glutamate synthetase and gamma-glutamyl hydrolase. (2308134)
1990
47
Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood. (2142722)
1990
48
Mutation of the insulin receptor at tyrosine 960 inhibits signal transmission but does not affect its tyrosine kinase activity. (2842060)
1988
49
Human cytochrome P-450 4 mRNA and gene: part of a multigene family that contains Alu sequences in its mRNA. (3462722)
1986
50
PARANOID SCHIZOPHRENIA IN A PATIENT WITH KLINEFELTER'S SYNDROME. (14220862)
1964

Variations for Pilocytic Astrocytoma

About this section

Expression for genes affiliated with Pilocytic Astrocytoma

About this section
Search GEO for disease gene expression data for Pilocytic Astrocytoma.

Pathways for genes affiliated with Pilocytic Astrocytoma

About this section

Pathways related to Pilocytic Astrocytoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 74)
idSuper pathwaysScoreTop Affiliating Genes
110.2NF1, PTPN11
210.1BRAF, KRAS, RAF1
310.0BRAF, HRAS, RAF1
410.0BRAF, HRAS, KRAS
510.0HRAS, KRAS, RAF1
610.0HRAS, PTPN11, RAF1
7
Show member pathways
10.0HRAS, PTPN11, RAF1
810.0HRAS, PTPN11, RAF1
910.0HRAS, PTPN11, RAF1
109.9BRAF, HRAS, KRAS, RAF1
11
Show member pathways
9.9BRAF, HRAS, KRAS, RAF1
129.9BRAF, HRAS, KRAS, RAF1
139.9BRAF, HRAS, KRAS, RAF1
14
Show member pathways
9.9BRAF, HRAS, KRAS, RAF1
159.8BRAF, CDKN2A, HRAS, RAF1
169.8HRAS, KRAS, PTPN11, RAF1
179.8HRAS, KRAS, PTPN11, RAF1
189.8FGFR1, GFAP, OLIG2, SOX10
19
Show member pathways
9.8ERBB3, HRAS, KRAS, NF1
209.8ERBB3, HRAS, PTPN11, RAF1
219.7FGFR1, HRAS, IDH1, KRAS, RAF1
22
Show member pathways
9.7BRAF, HRAS, KRAS, PTPN11, RAF1
23
Show member pathways
9.7BRAF, HRAS, KRAS, PTPN11, RAF1
249.7BRAF, CDKN2A, HRAS, KRAS, RAF1
259.7HRAS, KRAS, PTPN11, RAF1, SRGAP3
26
Show member pathways
9.7BRAF, ERBB3, HRAS, KRAS, RAF1
27
Show member pathways
9.7BRAF, ERBB3, HRAS, KRAS, RAF1
28
Show member pathways
9.7FGFR1, HRAS, KRAS, PTPN11, RAF1
299.7CDKN2A, ERBB3, HRAS, KRAS, RAF1
30
Show member pathways
9.6FGFR1, HRAS, KDR, KRAS, RAF1
319.6FGFR1, GFAP, OLIG2, SOX10, SYP
329.6BRAF, CDKN2A, FGFR1, HRAS, KRAS, RAF1
339.6BRAF, CDKN2A, HRAS, KRAS, NF1, RAF1
34
Show member pathways
9.6BRAF, ERBB3, FGFR1, KDR, KRAS, RAF1
35
Show member pathways
9.6BRAF, CDKN2A, HRAS, KRAS, PTPN11, RAF1
369.5BRAF, FGFR1, HRAS, KDR, KRAS, RAF1
37
Show member pathways
9.5BRAF, FGFR1, HRAS, KDR, KRAS, RAF1
389.5BRAF, FGFR1, HRAS, KRAS, NF1, NTRK2
39
Show member pathways
9.5ERBB3, FGFR1, HRAS, KDR, KRAS, NTRK2
40
Show member pathways
9.4BRAF, ERBB3, FGFR1, HRAS, KRAS, NTRK2
41
Show member pathways
9.4BRAF, ERBB3, FGFR1, KDR, KRAS, NTRK2
42
Show member pathways
9.4BRAF, ERBB3, HRAS, KRAS, NTRK2, PTPN11
43
Show member pathways
9.4BRAF, FGFR1, HRAS, KDR, KRAS, NTRK2
44
Show member pathways
9.4BRAF, HRAS, KDR, KRAS, NF1, PTPN11
45
Show member pathways
9.3BRAF, CDKN2A, ERBB3, FGFR1, HRAS, KRAS
46
Show member pathways
9.2BRAF, FGFR1, HRAS, KDR, KRAS, NF1
47
Show member pathways
9.2BRAF, ERBB3, FGFR1, HRAS, KDR, KRAS
489.2BRAF, ERBB3, FGFR1, HRAS, KDR, KRAS
49
Show member pathways
8.9BRAF, ERBB3, FGFR1, HRAS, KDR, KRAS
50
Show member pathways
8.6BRAF, CDKN2A, ERBB3, FGFR1, GFAP, HRAS

GO Terms for genes affiliated with Pilocytic Astrocytoma

About this section

Cellular components related to Pilocytic Astrocytoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1intracellularGO:00056229.9APOD, BRAF, GFAP, NTRK2

Biological processes related to Pilocytic Astrocytoma according to GeneCards Suite gene sharing:

(show all 25)
idNameGO IDScoreTop Affiliating Genes
1forebrain astrocyte developmentGO:002189710.9KRAS, NF1
2positive regulation of axonogenesisGO:005077210.9BRAF, NTRK2
3central nervous system neuron developmentGO:002195410.8FGFR1, NTRK2
4regulation of synaptic transmission, GABAergicGO:003222810.8KRAS, NF1
5negative regulation of cell-matrix adhesionGO:000195310.8CDKN2A, NF1
6wound healingGO:004206010.6ERBB3, NF1, RAF1
7regulation of phosphatidylinositol 3-kinase signalingGO:001406610.6ERBB3, FGFR1, PTPN11
8ERBB2 signaling pathwayGO:003812810.4ERBB3, HRAS, KRAS
9peptidyl-tyrosine phosphorylationGO:001810810.4ERBB3, FGFR1, KDR
10transmembrane receptor protein tyrosine kinase signaling pathwayGO:000716910.4ERBB3, KDR, NTRK2
11Ras protein signal transductionGO:000726510.3BRAF, CDKN2A, FGFR1, RAF1
12positive regulation of phosphatidylinositol 3-kinase signalingGO:001406810.3ERBB3, FGFR1, KDR, NTRK2
13MAPK cascadeGO:000016510.2FGFR1, HRAS, KRAS, NF1
14negative regulation of neuron apoptotic processGO:004352410.2BRAF, ERBB3, HRAS, KRAS, NTRK2
15leukocyte migrationGO:005090010.1HRAS, KRAS, PTPN11
16vascular endothelial growth factor receptor signaling pathwayGO:00480109.9BRAF, FGFR1, HRAS, KRAS, NF1, RAF1
17epidermal growth factor receptor signaling pathwayGO:00071739.9BRAF, FGFR1, HRAS, KRAS, NF1, PTPN11
18Fc-epsilon receptor signaling pathwayGO:00380959.9ERBB3, FGFR1, NF1, PTPN11
19activation of MAPKK activityGO:00001869.8BRAF, ERBB3, FGFR1, HRAS, KRAS, NF1
20fibroblast growth factor receptor signaling pathwayGO:00085439.7BRAF, ERBB3, FGFR1, HRAS, KRAS, NF1
21regulation of long-term neuronal synaptic plasticityGO:00481699.7HRAS, KRAS, NF1
22axon guidanceGO:00074119.6BRAF, ERBB3, FGFR1, HRAS, KRAS, RAF1
23insulin receptor signaling pathwayGO:00082869.6BRAF, ERBB3, FGFR1, HRAS, KRAS, NF1
24neurotrophin TRK receptor signaling pathwayGO:00480119.3BRAF, ERBB3, FGFR1, HRAS, KRAS, NF1
25innate immune responseGO:00450879.3BRAF, ERBB3, FGFR1, HRAS, KRAS, NF1

Molecular functions related to Pilocytic Astrocytoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1receptor signaling protein tyrosine kinase activityGO:000471610.4ERBB3, KDR
2protein tyrosine kinase activityGO:00047139.8ERBB3, FGFR1, KDR, NTRK2

Sources for Pilocytic Astrocytoma

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet